Mutual Freedom to Operate for Combination Inventions. (i) Lilly hereby grants to Athenex a non-exclusive, worldwide, royalty-free, fully paid-up license, transferable and sublicensable, to any patent owned or controlled by Lilly which (a) has a priority claim that is earlier than the initiation of the Study (i.e., first dosing of the first patient in the Study) and (b) claims the Combination, in order to practice such Combination for all purposes.
Mutual Freedom to Operate for Combination Inventions. [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed.
Mutual Freedom to Operate for Combination Inventions. (i) Vaccinex hereby grants to Merck a perpetual, irrevocable, non-exclusive, worldwide, royalty-free, fully paid-up license, transferable and sublicensable, under any claims in any patent owned or controlled by Vaccinex that was filed or includes a priority claim to an application that was filed prior to the initiation of the Study (i.e., first dosing of the first patient in the Study), or issues from any patent applications filed at any time and relating to an invention conceived of and owned or controlled by Vaccinex prior to initiation of the Study, which claims (a) specifically recite a product combining, or a use or method of use of both the Vaccinex Compound or a Vaccinex Class Compound, on the one hand, and Merck Compound or an Merck Class Compound, on the other hand, and (b) have been supported, in the patent disclosure or during prosecution with the applicable patent authority, by filing of or reference to Clinical Data, to practice the Combination for all purposes.
Mutual Freedom to Operate for Combination Inventions. (i) With respect to any patent owned or controlled by Vaximm at any time prior to the initiation of the Study (i.e., the first dosing of the first patient in the Study) until Study Completion, or issuing from any patent applications filed at any time and relating to an invention conceived of and owned or controlled by Vaximm prior to initiation of the Study until Study Completion (other than, in each case, an Invention), which patent specifically recites a product combining, or a use or method of use of both a Vaximm Class Compound and an Alliance Class Compound, Vaximm hereby grants to the Alliance a perpetual, irrevocable, non-exclusive, worldwide, royalty-free, fully paid-up, transferable and sublicensable license under any particular claims in any such patents that specifically recite a product combining, or a use or method of use of both, a Vaximm Class Compound and an Alliance Class Compound, to use, manufacture, sell or otherwise exploit the Alliance Compound for use in a Combination for all purposes.
Mutual Freedom to Operate for Combination Inventions. 10.5.1 [***], Checkmate shall grant, and hereby does grant to Pfizer a perpetual, irrevocable, non-exclusive, worldwide, royalty-free, fully paid-up license, transferable and sublicensable, under any particular claims in any patent owned or controlled by Checkmate that was filed or includes a priority claim to an application that was filed prior to the initiation of the Study (i.e., first dosing of the first patient in the Study), or issues from any patent applications filed at any time and relating to an invention conceived of and owned or controlled by Checkmate prior to initiation of the Study, that specifically recite a product combining, or a use or method of use of (i) a Checkmate Class Compound with a respective Pfizer Class Compound or (ii) a Checkmate Class Compound, a respective Pfizer Class Compound and an Alliance Class Compound, in each case to practice the Class Combination for all purposes.
Mutual Freedom to Operate for Combination Inventions. 10.4.1 Pfizer hereby grants to Ideaya (i) during the term of this Agreement and (ii) perpetually contingent upon and effective as of Regulatory Approval for the commercial sale of the Combination, an irrevocable, non-exclusive, worldwide, royalty-free, fully paid-up license, transferable and sublicensable, to any patent claims directed to the Combination in any patent application or patent owned or controlled by Pfizer which (a) has a priority claim that is earlier than the initiation of the Study (i.e., first dosing of the first patient in the Study) and (b) claims the Combination, solely in order to practice such Combination for all purposes.
Mutual Freedom to Operate for Combination Inventions. 10.5.1 Amgen hereby grants to Ideaya a non-exclusive, worldwide, royalty-free, fully paid-up license, transferable and sublicensable, to any patent Controlled by Amgen that (a) is in Amgen’s Background IP and (b) claims or covers the Combination solely for purposes of conducting the Study during the Term.
Mutual Freedom to Operate for Combination Inventions. (i) Advaxis hereby grants to Merck a perpetual, irrevocable, non-exclusive, worldwide, royalty-free, fully paid-up license, transferable and sublicensable, to any patent owned or controlled by Advaxis which (a) has a priority claim that is earlier than the initiation of the Study (i.e., first dosing of the first patient in the Study) and (b) claims the Combination, in order to practice such Combination for all purposes.
Mutual Freedom to Operate for Combination Inventions. 10.4.1. Company License to MSD. Company hereby grants to MSD [***].
Mutual Freedom to Operate for Combination Inventions. 10.4.1 Sponsor hereby grants to Lilly a non-exclusive, worldwide, royalty- free, fully paid-up license, transferable and sublicensable, [***]. 10.4.2 Lilly hereby grants to Sponsor a non-exclusive, worldwide, royalty- free, fully paid-up license, transferable and sublicensable, [***]. 10.4.3 For clarity, the terms of this Section 10.4 do not provide Lilly or Sponsor with any rights, title or interest or any license to the other Party's background intellectual property which does not claim the Combination (i.e., intellectual property owned or licensed by either Party which does not constitute an Invention and does not claim the Combination) except as necessary to conduct the Study. ARTICLE 11.
